Skip to main content
. 2022 Dec 5;41(9):1725–1734. doi: 10.1200/JCO.22.00830

FIG 1.

FIG 1.

A waterfall plot shows best tumor responses in all 30 patients. aPatients had overall progressive disease with < 20% increase on target lesions but had new nontarget lesions. bPatients had rapid clinical deterioration before a restaging imaging study could be performed, who are documented a 21% tumor increase. cOne patient was still on treatment at the last updated date on May 24, 2022.